Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829600 | 0.79 | HSP90AB1 (0.49) | HRH3HSP90AB1MAPTNOS3NOS1 | |
| SCHEMBL15689263 | 0.79 | HSP90AB1 (0.40) | HSP90AB1MAPTNOS3NOS1NOS2 | |
| SCHEMBL191457 | 0.77 | KMT2A (0.59) | HSP90AB1MAPTKMT2AHSP90AA1MEN1 | |
| SCHEMBL8126538 | 0.77 | MAPT (0.34) | MAPTNOS3NOS1NOS2IDO1 | |
| SCHEMBL14163375 | 0.77 | KMT2A (0.42) | HRH4HRH3HSP90AB1MAPTKMT2A | |
| SCHEMBL754084 | 0.76 | KMT2A (0.40) | HRH4HRH3MAPTKMT2ADYRK1A | |
| SCHEMBL27828127 | 0.74 | ALDH1A1 (0.47) | HSP90AB1HSP90AA1NPC1RAB9A | |
| SCHEMBL23240417 | 0.73 | TRPM8 (0.35) | MAPTKMT2ANOS3NOS1NOS2 | |
| SCHEMBL10620437 | 0.73 | HRH4 (0.38) | HRH4HSP90AB1MAPTKMT2AHSP90AA1 | |
| SCHEMBL96485 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340633-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-20170049772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2017-02-23 | — | — | US | disclosed |
| US-9487772-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2016-11-08 | — | — | US | disclosed |
| US-9221822-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-12-29 | — | — | US | disclosed |
| US-9221822-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-12-29 | — | — | US | disclosed |
| EP-2923734-A1 | Purine analogues and their use as immunosuppressive agents | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2015-09-30 | — | — | EP | disclosed |
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2015-02-05 | — | — | US | disclosed |
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2015-02-05 | — | — | US | disclosed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | disclosed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | disclosed |
| EP-1467996-B1 | PYRIMIDOTRIAZINES AS PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-11-30 | — | — | EP | disclosed |
| EP-1467996-A1 | PYRIMIDOTRIAZINES AS PHOSPHATASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-20 | — | — | EP | disclosed |
| US-6642381-B2 | Containing tertiary alkyl amine, pyrollidine, morpholine or piperazine moieties; optionally containing unsubstituted or substituted phenyl or naphthyl groups | HOFFMAN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030153756-A1 | Pyrimido[5,4-e] [1,2,4]triazine-5, 7-diamine compounds as protein tyrosine phosphatase inhibitors | GUERTIN KEVIN RICHARD (US) | 2003-08-14 | — | — | US | disclosed |
| WO-2003055883-A1 | PYRIMIDOTRIAZINES AS PHOSPHATASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-10 | — | — | WO | disclosed |
| US-4761475-A | 2,4-diaminopyrimidines substituted with heterobicyclomethyl radicals at the 5 position useful as antibacterials | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 1988-08-02 | — | — | US | disclosed |
| US-4587342-A | 2,4-diamino-(substituted-benzopyran(quinolyl,isoquinoly)methyl)pyrimidines useful as antibacterials | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 1986-05-06 | — | — | US | disclosed |
| EP-0051879-B1 | SUBSTITUTED PYRIMIDINES, THEIR SYNTHESIS AND COMPOSITIONS CONTAINING THEM, THEIR USE IN MEDICINE AND INTERMEDIATES FOR MAKING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-02-05 | — | — | EP | disclosed |
| US-4568744-A | ANTIBACTERICIDES AND DIRUETIC INTERMEDIATES | BURROUGHS WELLCOME CO. (US) | 1986-02-04 | — | — | US | disclosed |
| EP-0051879-A2 | Substituted pyrimidines, their synthesis and compositions containing them, their use in medicine and intermediates for making them | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340633-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | HRH4 3250/4885HRH3 2427/4885HSP90AB1 567/4885 |
| US-20030153756-A1 | Pyrimido[5,4-e] [1,2,4]triazine-5, 7-diamine compounds as protein tyrosine phosphatase inhibitors | PTPN5, PPP5C, PTPA | HRH4 3225/4885HRH3 4533/4885HSP90AB1 2434/4885 |
| US-20170049772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | HRH4 3437/4885HRH3 2519/4885HSP90AB1 584/4885 |
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | TPMT, STAT6, IL4 | HRH4 113/4885HRH3 418/4885HSP90AB1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.